2027 ICD-10-CM Diagnosis Code E75.22Gaucher disease

ICD-10-CM Codes›E00–E89›E70-E88›E75

ICD-10-CM E75.22
CMSSource: CMS FY 2027 ICD-10-CM dataset · Effective Oct 1, 2026 – Sep 30, 2027

E75.22 is a billable ICD-10-CM diagnosis code for gaucher disease. It is valid on HIPAA claims for fiscal year 2027 (October 1, 2026 through September 30, 2027) and groups to MS-DRG 642. Coders also document this condition as acute neuronopathic Gaucher's disease. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Other specified and unspecified nutritional and metabolic disorders.

For Medicare Advantage risk adjustment, E75.22 maps to CMS-HCC Category 49 (Specified Lysosomal Storage Disorders) under the V28 model, adding a risk factor of about 9.256 for a community, non-dual, aged beneficiary in payment year 2027.

Code Identity

ICD-10-CM Code
E75.22
Billable Status
Yes — Valid for Submission
Code Describes
Gaucher disease
Short Description
Gaucher disease
Same as the full description in the CMS dataset.
Parent Code
Other sphingolipidosis

Code Classification

ChapterE00–E89Endocrine, nutritional and metabolic diseases
SectionE70-E88Metabolic disorders
CategoryE75Disorders of sphingolipid metabolism and other lipid storage disorders
This CodeE75.22Gaucher disease

Medicare Risk Adjustment (HCC)Billing

E75.22 maps to a payment category in the CMS-HCC model used to risk-adjust Medicare Advantage payments. Weights are the published community factors for payment year 2027.

CMS-HCC V28 Category (Payment Model)
HCC 49— Specified Lysosomal Storage Disorders
Payment HCC · PY 2027 one of 13 ICD-10-CM codes in this category
Risk Adjustment Factor (RAF) Weight
+9.256
community, non-dual, aged · ranges 1.528–13.778 across segments
Hierarchy
Top of its hierarchy
HCC 49 is not superseded by any other condition category
Prior Model (CMS-HCC V24)
HCC 23
V24 retired V28 pays 100% of MA risk scores since PY 2026
Other CMS Models
PACE (CMS-HCC V22): HCC 23 · ESRD (V21): HCC 23 · ESRD (V24): HCC 23
ESRD V21 weights: 0.013 dialysis, 0.234–0.359 functioning graft · ESRD V24 weights: 0.036 dialysis, 0.217–0.390 functioning graft
Part D (RxHCC)
RxHCC 41 — Lysosomal Storage Disorders
also risk-adjusts in the Part D prescription drug model (V08)

Source: CMS Payment Year 2027 risk adjustment mappings and model software. Weights are relative factors, not dollar amounts; a beneficiary's total RAF also includes demographics and interactions. Browse all CMS-HCC categories.

Approximate SynonymsGuidance

Alternate terms and clinical phrases that map to this code.

  • Acute neuronopathic Gaucher's disease
  • Atypical Gaucher disease due to saposin C deficiency
  • Cerebral degeneration in Gaucher's disease
  • Chronic non-neuropathic Gaucher's disease
  • Gaucher disease with ophthalmoplegia and cardiovascular calcification
  • Gaucher's disease
  • Perinatal lethal Gaucher disease
  • Subacute neuronopathic Gaucher's disease

Instructional NotesGuidance

Instructions from the official ICD-10-CM Tabular List that apply to E75.22: its own notes plus those printed at E75.2, E75, block E70-E88, and Chapter 4. A note printed at a category, block or chapter applies to every code under it.

Excludes1

Not coded here: the excluded code is never reported together with this one, unless the two conditions are unrelated.

From E75.2 Other sphingolipidosis applies to 15 codes
  • adrenoleukodystrophy [Addison-Schilder] (E71.528)
From E75 Disorders of sphingolipid metabolism and other lipid storage disorders applies to 26 codes
From Block E70-E88 Metabolic disorders applies to 286 codes
  • androgen insensitivity syndrome (E34.5-)
  • congenital adrenal hyperplasia (E25.0)
  • hemolytic anemias attributable to enzyme disorders (D55.-)
  • Marfan syndrome (Q87.4-)
  • 5-alpha-reductase deficiency (E29.1)
From Chapter 4 (E00-E89) Endocrine, nutritional and metabolic diseases applies to 973 codes
  • transitory endocrine and metabolic disorders specific to newborn (P70-P74)

Excludes2

Not included here: the excluded condition is not part of this code, but a patient may have both, so both codes may be reported.

From Block E70-E88 Metabolic disorders applies to 286 codes
  • Ehlers-Danlos syndromes (Q79.6-)

Notes

General instructions on how these codes are used.

From Chapter 4 (E00-E89) Endocrine, nutritional and metabolic diseases applies to 973 codes
  • All neoplasms, whether functionally active or not, are classified in Chapter 2. Appropriate codes in this chapter (i.e. E05.8, E07.0, E16-E31, E34.-) may be used as additional codes to indicate either functional activity by neoplasms and ectopic endocrine tissue or hyperfunction and hypofunction of endocrine glands associated with neoplasms and other conditions classified elsewhere.

Source: CMS ICD-10-CM Tabular List. How to read instructional notes.

Referenced in Other NotesGuidance

Instructional notes printed at other codes that name E75.22, its category, or a range that includes it.

Excludes1 2

These codes carry an Excludes1 note naming E75.22: they are not reported together with it, unless the two conditions are unrelated.

  • R79 Other abnormal findings of blood chemistry
    specific findings indicating disorder of lipid metabolism (E75.-) names E75.-, which includes this code
  • E78 Disorders of lipoprotein metabolism and other lipidemias
    sphingolipidosis (E75.0-E75.3) names E75.0-E75.3, which includes this code

Code First 2

These codes say to code first a condition named in the note, and E75.22 is one of the conditions named.

  • G73.7 Myopathy in diseases classified elsewhere
    lipid storage disorders (E75.-) names E75.-, which includes this code
  • H36 Retinal disorders in diseases classified elsewhere
    lipid storage disorders (E75.-) names E75.-, which includes this code

Code Also 1

These codes say E75.22 may also be needed to fully describe the condition. The note gives no sequencing direction.

  • I27.29 Other secondary pulmonary hypertension
    Gaucher disease (E75.22)

Index to Diseases and InjuriesGuidance

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR END016
Other specified and unspecified nutritional and metabolic disorders
Default principal diagnosis: inpatient Yes · outpatient Yes

Clinical InformationClinical

  • Gaucher Disease

    an autosomal recessive disorder caused by a deficiency of acid beta-glucosidase (glucosylceramidase) leading to intralysosomal accumulation of glycosylceramide mainly in cells of the mononuclear phagocyte system. the characteristic gaucher cells, glycosphingolipid-filled histiocytes, displace normal cells in bone marrow and visceral organs causing skeletal deterioration, hepatosplenomegaly, and organ dysfunction. there are several subtypes based on the presence and severity of neurological involvement.

Patient EducationClinical

Gaucher Disease

Gaucher disease is a rare, inherited disorder. It is a type of lipid metabolism disorder. If you have it, you do not have enough of an enzyme called glucocerebrosidase. This causes too much of a fatty substance to build up in your spleen, liver, lungs, bones and, sometimes, your brain. This prevents these organs from working properly.

Read the full article at MedlinePlus

Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.

Convert E75.22 to ICD-9-CMHistory

The closest ICD-9-CM equivalents under the General Equivalence Mappings.

ICD-9-CM
272.7 Lipidoses
Approximate The match is approximate rather than exact.

Code HistoryHistory

FY 2016AddedAdded to the ICD-10-CM code setEffective October 1, 2015, the first year of ICD-10-CM.
FY 2017–2026No changes
FY 2027CurrentCurrent code set, no changesEffective October 1, 2026 through September 30, 2027.

Questions About E75.22Overview

What is the ICD-10 code for gaucher disease?

The ICD-10-CM code for gaucher disease is E75.22 (sometimes written as E7522). It is billable on HIPAA-covered claims from October 1, 2026 through September 30, 2027.

Is E75.22 (Other sphingolipidosis) a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report gaucher disease on HIPAA-covered claims from October 1, 2026 through September 30, 2027.

What MS-DRG does E75.22 group to?

When gaucher disease is the principal diagnosis on an inpatient stay, it groups to MS-DRG 642 (inborn and Other Disorders of Metabolism), which carries a relative weight of 1.3226. Higher weights mean higher Medicare reimbursement.

Can E75.22 be reported with E71.528?

Not as a rule. The Excludes1 note at E75.2, which applies to E75.22, lists "adrenoleukodystrophy [Addison-Schilder] (E71.528)". An Excludes1 note means the excluded code is never reported together with this one; the only exception is when the two conditions are unrelated to each other (Official Guidelines, Section I.A.12.a).

What is the ICD-9 equivalent of E75.22?

Under the General Equivalence Mappings, gaucher disease converts to ICD-9-CM 272.7 (lipidoses). The mapping is approximate, so confirm the match fits the documentation.

What HCC is E75.22?

E75.22 (gaucher disease) maps to CMS-HCC Category 49 (Specified Lysosomal Storage Disorders), commonly written as HCC 49, in the CMS-HCC V28 model used for Medicare Advantage risk adjustment in payment year 2027. It mapped to HCC 23 under the retired V24 model. It also maps in the PACE (CMS-HCC V22), ESRD (V21), and ESRD (V24) models. In the Part D prescription drug model it maps to RxHCC 41.

Does E75.22 risk-adjust for Medicare Advantage payment?

Yes. When documented and reported on a Medicare Advantage encounter, E75.22 adds a risk adjustment factor of about 9.256 to the beneficiary's RAF score for a community, non-dual, aged enrollee (published V28 weights range from 1.528 to 13.778 depending on the payment segment). HCC 49 sits at the top of its hierarchy, so no other condition category supersedes it. See the full factor table on the HCC 49 category page.